Linking Brain Imaging With Genetics Helps Identify New Risk Profile for Depression

Printer-friendly versionPrinter-friendly version
Andrew M. McIntosh, M.D. - Brain and behavior research expert on depression
Andrew M. McIntosh, M.D.

Andrew M. McIntosh, M.D., Chair of Biological Psychiatry at the University of Edinburgh, U.K., used his 2010 NARSAD Independent Investigator Grant to probe whether abnormalities in white matter integrity associated with mood disorders (bipolar disorder or BD and major depressive disorder or MDD) can be linked to genetic risk for these illnesses. More than 350 million people of all ages suffer from depression (including both BD and MDD) worldwide, according to the World Health Organization, and it is the leading cause of global disability. Dr. McIntosh and colleagues’ research aims to establish a more precise biological risk profile for these illnesses to facilitate early detection and intervention.

The research team identified a crucial correlation between mood disorder risk genes and a specific biological trait that can be seen in functional brain imaging studies. The trait has to do with what scientists call the “integrity” of the brain’s connections (i.e., white matter). An overall risk score reflecting the accumulation of multiple mood disorder genes was determined for individuals who were not ill but had a close relative with bipolar disorder. This mood disorder risk score was found to correlate with reduced white matter integrity, viewed via brain scan.

The findings, published online in Biological Psychiatry on March 4, 2013, support the hypothesis that vulnerability to depression is caused by malfunctioning circuitry in the brain, where impaired connectivity contributes to the development of mood disorder. The results further indicate a genetic origin of these deficits, offering the potential to identify specific biological pathways involved in the illness and to develop more precise treatment options for those affected.

Article comments

Thank God for this research. After decades of making little or no progress in terms of understanding the underpinnings of these mood disorders it seems as though we are finally getting somewhere.
As Churchill once said: - “Now this is not the end. It is not even the beginning of the end; but it is, perhaps, the end of the beginning.”
On a technical note, I wonder if it is possible to tie this research in with the fast acting antidepressant actions noted with substances such as Ketamine and more recently isoflurane?

Add new comment

comments

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Please note that researchers cannot give specific recommendations or advice about treatment; diagnosis and treatment are complex and highly individualized processes that require comprehensive face-to- face assessment. Please visit our "Ask an Expert" section to see a list of Q & A with NARSAD Grantees.
By submitting this form, you accept the Mollom privacy policy.